Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD)

被引:7
作者
A-Kader, Hassan H. [1 ]
机构
[1] Univ Arizona, Dept Pediat, Div Gastroenterol Hepatol & Nutr, 1501 N Campbell Ave, Tucson, AZ 85724 USA
关键词
Nonalcoholic fatty liver disease; NASH; NAFLD; NOFLD; lysosomal acid lipase deficiency; LAL-D; obesity; metabolic syndrome; ESTER STORAGE DISEASE; FAMILIAL COMBINED HYPERLIPIDEMIA; INFLAMMATORY-BOWEL-DISEASE; STEM-CELL TRANSPLANTATION; LOW-DENSITY LIPOPROTEIN; CHRONIC HEPATITIS-C; WOLMAN-DISEASE; SUBCLINICAL COURSE; ENZYME DEFICIENCY; SEBELIPASE ALPHA;
D O I
10.1080/17474124.2017.1343144
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: With the growing obesity epidemic, nonalcoholic fatty liver disease (NAFLD) is rapidly becoming one of the leading causes of liver disease worldwide. Although obesity is a main risk factor for the development of NAFLD, it can also develop in lean subjects and can be encountered in different clinical setting and in association with an array of genetic, metabolic, nutritional, infectious and drug-induced disorders. Areas covered: This article discusses causes of fatty liver in non-obese subjects focusing on Lysosomal acid lipase deficiency (LAL-D), a commonly overlooked disorder reviewing its prevalence, genetics, pathogenesis, clinical features, diagnosis and treatment. It will also review other causes of non-alcoholic fatty liver disease, which can be encountered in the absence of obesity and metabolic syndrome. Expert commentary: Although the prevalence of LAL-D has been estimated in the range of 1 in 40,000 and 1 in 300,000, this estimate is much more than the identified cases reported in the literature, which suggests that that the disease may be considerably under-diagnosed. There is a pressing need to educate clinicians about the disease, especially with the development of new promising therapeutic modalities.
引用
收藏
页码:911 / 924
页数:14
相关论文
共 150 条
[1]   Nonalcoholic fatty liver disease in children living in the obeseogenic society [J].
A-Kader, H. Hesham .
WORLD JOURNAL OF PEDIATRICS, 2009, 5 (04) :245-254
[2]   THE TREATMENT OF COLESTERYL STORAGE DISEASE (CESD) BY EZETIMIBE MONOTHERAPY [J].
Abello, F. ;
Guardamagna, O. ;
Baracco, V. ;
Bonardi, R. .
ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) :28-28
[3]   GENERALIZED XANTHOMATOSIS WITH CALCIFIED ADRENALS [J].
ABRAMOV, A ;
SCHORR, S ;
WOLMAN, M .
AMA JOURNAL OF DISEASES OF CHILDREN, 1956, 91 (03) :282-286
[4]   Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors [J].
Akuta, N ;
Suzuki, F ;
Tsubota, A ;
Suzuki, Y ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :831-836
[5]  
Ambler GK, 2013, JIMD REP, V8, P41, DOI 10.1007/8904_2012_155
[6]   Lysosomal acid lipase mutations that determine phenotype in Wolman and cholesterol ester storage disease [J].
Anderson, RA ;
Bryson, GM ;
Parks, JS .
MOLECULAR GENETICS AND METABOLISM, 1999, 68 (03) :333-345
[7]  
ANDERSON RA, 1991, J BIOL CHEM, V266, P22479
[8]   Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[9]  
[Anonymous], COCHRANE DATABASE SY
[10]   ORTHOTOPIC LIVER-TRANSPLANTATION FOR CHOLESTERYL ESTER STORAGE DISEASE [J].
ARTERBURN, JN ;
LEE, WM ;
WOOD, RP ;
SHAW, BW ;
MARKIN, RS .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1991, 13 (04) :482-485